Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.81 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.81 |
| ▸ | PDE2A | O00408 | 1/20 | 0.81 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.81 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.81 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.81 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.81 |
| ▸ | LMNA | P02545 | 2/20 | 0.78 |
| ▸ | TP53 | P04637 | 1/20 | 0.78 |
| ▸ | NT5E | P21589 | 1/20 | 0.75 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.75 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.73 |
| ▸ | CA1 | P00915 | 1/20 | 0.72 |
| ▸ | CA2 | P00918 | 1/20 | 0.72 |
| ▸ | CA4 | P22748 | 1/20 | 0.72 |
| ▸ | CA9 | Q16790 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6837087 | 1.00 | ADORA3 (0.81) | ADORA3ADORA2APDE2AADORA1ADRA1A | |
| SCHEMBL19953842 | 1.00 | ADORA3 (0.81) | ADORA3ADORA2APDE2AADORA1ADRA1A | |
| SCHEMBL1663268 | 1.00 | ADORA3 (0.81) | ADORA3ADORA2APDE2AADORA1ADRA1A | |
| SCHEMBL20128458 | 1.00 | ADORA3 (0.81) | ADORA3ADORA2APDE2AADORA1ADRA1A | |
| SCHEMBL13863559 | 1.00 | ADORA3 (0.81) | ADORA3ADORA2APDE2AADORA1ADRA1A | |
| SCHEMBL104095 | 1.00 | ADORA3 (0.81) | ADORA3ADORA2APDE2AADORA1ADRA1A | |
| SCHEMBL104094 | 1.00 | ADORA3 (0.81) | ADORA3ADORA2APDE2AADORA1ADRA1A | |
| SCHEMBL1389446 | 1.00 | ADORA3 (0.81) | ADORA3ADORA2APDE2AADORA1ADRA1A | |
| SCHEMBL6886946 | 1.00 | ADORA3 (0.81) | ADORA3ADORA2APDE2AADORA1ADRA1A | |
| SCHEMBL4535914 | 1.00 | ADORA3 (0.81) | ADORA3ADORA2APDE2AADORA1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024346-A1 | CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF | RISEN SUZHOU PHARMA TECH CO LTD (CN) | 2024-01-25 | — | — | US | disclosed |
| EP-4251633-A1 | CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2023-10-04 | — | — | EP | disclosed |
| US-20230295213-A1 | CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF | RISEN SUZHOU PHARMA TECH CO LTD (CN) | 2023-09-21 | — | — | US | disclosed |
| CN-116546990-A | CD73 inhibitor and pharmaceutical application thereof | 润佳（苏州）医药科技有限公司 | 2023-08-04 | — | — | CN | disclosed |
| CN-110885352-B | CD73 inhibitor and pharmaceutical application thereof | 润佳（苏州）医药科技有限公司 | 2023-02-24 | — | — | CN | disclosed |
| US-11530234-B2 | CD73 inhibitors and pharmaceutical uses thereof | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2022-12-20 | — | — | US | disclosed |
| CN-112771061-B | CD73 inhibitor and pharmaceutical application thereof | 润佳（苏州）医药科技有限公司 | 2022-06-17 | — | — | CN | disclosed |
| WO-2022109741-A1 | CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2022-06-02 | — | — | WO | disclosed |
| EP-3849992-A1 | CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2021-07-21 | — | — | EP | disclosed |
| US-20210139526-A1 | CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF | RISEN (SUZHOU) PHARMA TECH Co.,Ltd. (CN) | 2021-05-13 | — | — | US | disclosed |
| CN-112771061-A | CD73 inhibitor and pharmaceutical application thereof | 润佳（苏州）医药科技有限公司 | 2021-05-07 | — | — | CN | disclosed |
| US-10881681-B2 | CD73 inhibitors and pharmaceutical uses thereof | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2021-01-05 | — | — | US | disclosed |
| WO-2020051686-A1 | CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF | RISEN (SUZHOU) PHARMA TECH CO. LTD. (CN) | 2020-03-19 | — | — | WO | disclosed |
| CN-110885352-A | CD73 inhibitor and pharmaceutical application thereof | 润佳（苏州）医药科技有限公司 | 2020-03-17 | — | — | CN | disclosed |
| US-20200078388-A1 | CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF | RISEN (SUZHOU) PHARMA TECH CO, LTD. (CN) | 2020-03-12 | — | — | US | disclosed |
| US-8101740-B2 | Positron emission tomography probes for imaging immune activation and selected cancers | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-01-24 | — | — | US | disclosed |
| EP-2200658-A2 | POSITRON EMISSION TOMOGRAPHY PROBES FOR IMAGING IMMUNE ACTIVATION AND SELECTED CANCERS | The Regents Of The University Of California (US) | 2010-06-30 | — | — | EP | disclosed |
| US-20090105184-A1 | POSITRON EMISSION TOMOGRAPHY PROBES FOR IMAGING IMMUNE ACTIVATION AND SELECTED CANCERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-04-23 | — | — | US | disclosed |
| WO-2009038795-A2 | POSITRON EMISSION TOMOGRAPHY PROBES FOR IMAGING IMMUNE ACTIVATION AND SELECTED CANCERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-03-26 | — | — | WO | disclosed |
| CN-101023072-A | Piperidinyl targeting compounds that selectively bind integrins | JANSSEN PHARMACEUTICA NV (BE) | 2007-08-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200078388-A1 | CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF | ENTPD5, ENTPD1, NT5E | ADORA3 35/4885ADORA2A 18/4885PDE2A 274/4885 |
| US-20230295213-A1 | CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF | ENTPD5, NT5E, ENTPD1 | ADORA3 34/4885ADORA2A 17/4885PDE2A 264/4885 |
| US-10881681-B2 | CD73 inhibitors and pharmaceutical uses thereof | ENTPD5, ENTPD1, NT5E | ADORA3 35/4885ADORA2A 18/4885PDE2A 274/4885 |
| US-20240024346-A1 | CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF | ENTPD5, NT5E, ENTPD1 | ADORA3 34/4885ADORA2A 17/4885PDE2A 264/4885 |
| US-11530234-B2 | CD73 inhibitors and pharmaceutical uses thereof | ENTPD5, ENTPD1, NT5E | ADORA3 35/4885ADORA2A 18/4885PDE2A 274/4885 |
| US-20210139526-A1 | CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF | ENTPD5, ENTPD1, NT5E | ADORA3 35/4885ADORA2A 18/4885PDE2A 274/4885 |
| US-20090105184-A1 | POSITRON EMISSION TOMOGRAPHY PROBES FOR IMAGING IMMUNE ACTIVATION AND SELECTED CANCERS | PAICS, ADA, DCTD | ADORA3 145/4885ADORA2A 55/4885PDE2A 1565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.